Natalizumab: bound to rebound?
Schiess
Nicoline
N
Calabresi
Peter A
PA
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007964:Leukocytosis / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D000069442:Natalizumab; D017063:Outcome Assessment, Health Care / Q000379:methods; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab